|
Sign In to gain access to subscriptions and/or personal tools.
|
Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 4,
489-492 (2006)
DOI: 10.1177/1076029606293439
Chronic Refractory Idiopathic Thrombocytopenic Purpura (ITP) and Anti-CD20 Monoclonal Antibody: A Case Report
S. Z. Latifzadeh, MD
Department of Hemato-Oncology, Rasule-Akram General Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
V. Entezari, MD
Department of Hemato-Oncology, Rasule-Akram General Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran, e_vahid{at}yahoo.com
Idiopathic thrombocytopenic purpura (ITP) is an immune-mediated disorder characterized by accelerated and premature destruction of platelets by reticuloendothelial system. CD20, a trans-membrane B-cell-specific antigen, is a potential target for treatment of certain malignant and nonmalignant plasma cell disorders including refractory ITP. Rituximab is a genetically engineered human anti-CD20 monoclonal antibody, which is approved for the treatment of low-grade non-Hodgkin’s lymphoma. Recent clinical reports suggest that rituximab may be useful in treating certain patients with chronic refractory ITP. A 59-year-old woman with refractory ITP was placed on rituximab (four weekly doses of 375 mg/m2) and her condition and platelet count were observed for 18 months. There was a gradual increase in platelet count and she was symptom free in this period and no side effects of the drug were reported. Anti-CD20 antibodies are likely to be used in the treatment of refractory ITP cases, but further studies about treatment schedule and criteria for patient selection should be done.
Key Words: Idiopathic thrombocytopenic purpura • Anti CD20 antibody • Rituximab
References
- George JN, El-Havake MA, Raskob GE. Chronic idiopathic thrombocytopenic Purpura. N Engl J Med 1995, 331: 207-207.
- Bussel JB. Overview of idiopathic thrombocytopenic purpura: New approach to refractory patients. Semin Oncol 2000; 27(6 Suppl 12): 91-91.[ISI][Medline]
[Order article via Infotrieve]
- Saleh MN, Gutheil J, Moore M, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000; 27(6 Suppl 12): 99-99.[ISI][Medline]
[Order article via Infotrieve]
- Treon SP, Anderson KC. The use of rituximab in treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000; 27(6 Suppl 12): 79-79.[ISI][Medline]
[Order article via Infotrieve]
- Choueiri T, Lichtin AE. Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab. Am J Med 2002; 113: 700-700.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98(4): 952-952.[Abstract/Free Full Text]
- George JN, Kojouri K, Perdue JJ, Vesely SK. Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol 2000; 37(3): 290-290.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Patel K, Berman J, Ferber A, Caro J. Refractory autoimmune thrombocytopenic purpura treatment with rituximab. Am J Hematol 2001; 67(1): 59-59.[ISI][Medline]
[Order article via Infotrieve]
- Shvidel L, Klepfish A, Berrebi A. Successful treatment with rituximab for relapsing immune thrombocytopenic purpura (ITP) associated with low-grade non-Hodgkin’s lymphoma. Am J Hematol 2001; 67(3): 213-213.[ISI][Medline]
[Order article via Infotrieve]
- Perotta A, Sunneberg TA, Scott J, et al. Rituxan in the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Blood 1999; 94(Suppl 1): 49a-49a.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
|
